Gastrointestinal Stromal Tumors clinical trials
The registry lists 343 studies for Gastrointestinal Stromal Tumors across more than 10 countries. 61 are recruiting or about to start. 252 of them are mainly about Gastrointestinal Stromal Tumors (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13.
Get an email when these change. Save the Gastrointestinal Stromal Tumors studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
Novartis Pharmaceuticals (27) · National Cancer Institute (NCI) (23) · Asan Medical Center (18) · Pfizer (9) · Deciphera Pharmaceuticals, LLC (9) · European Organisation for Research and Treatment of Cancer - EORTC (7) · M.D. Anderson Cancer Center (7) · Bayer (7)
What is being tested here
Drugs under test in Gastrointestinal Stromal Tumors studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Imatinib | 8 | 12 | 48 |
| IDRX-42 | 4 | 2 | 5 |
| Envafolimab | 2 | 0 | 2 |
| Apatinib | 2 | 0 | 2 |
| Sunitinib | 1 | 2 | 13 |
| Regorafenib | 1 | 1 | 10 |
| Ripretinib | 1 | 3 | 9 |
| Bezuclastinib | 1 | 1 | 3 |
| Temozolomide | 1 | 0 | 3 |
| Paclitaxel | 1 | 0 | 3 |
Drug classes tested here Tyrosine kinase inhibitors (TKIs) 21 open · Immune checkpoint inhibitors 2 open · Angiogenesis inhibitors 1 open · Antimitotic agents 1 open · Antimetabolites 6
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest
- Nov 2026MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) · Memorial Sloan Kettering Cancer Center
- Dec 2026A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101) · Taiho Pharmaceutical Co., Ltd.
- Dec 2026The Efficacy and Safety of Temozolomide in SDH-deficient GIST · Asan Medical Center
- Dec 2026ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST · University of Miami
- Dec 2026Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients · Royal Marsden NHS Foundation Trust
- Mar 2027A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies · Deciphera Pharmaceuticals, LLC
- Mar 2027First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors · IDRX, Inc., a wholly owned subsidiary of GSK, LLC
- Mar 2027GIST Oral Paclitaxel(Liporaxel) · Asan Medical Center
- Apr 2027Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery · Chinese University of Hong Kong
- Apr 2027A Novel Two-Tooth Clip for ESD and EFTR of GIST · Affiliated Hospital to Academy of Military Medical Sciences
Who these studies take
Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger. 6 (12%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (4%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 5 (10%) | 5 (10%) |
| 18 | 44 (90%) | 44 (90%) |
| 30 | 48 (98%) | 48 (98%) |
| 40 | 48 (98%) | 48 (98%) |
| 50 | 48 (98%) | 48 (98%) |
| 65 | 48 (98%) | 48 (98%) |
| 75 | 48 (98%) | 48 (98%) |
| 85 | 43 (88%) | 43 (88%) |
Across all 343 studies, recruiting or not: 10% stop at 75 or younger and 3% at 65; 13% take children; 1% are for women only and 1% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Gastrointestinal Stromal Tumors studies take
Of 47 phase 2 interventional studies under Gastrointestinal Stromal Tumors, half reached primary completion within 62 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 35 mo26–77 · 21 studies | — | — |
| Phase 2 | 62 mo38–92 · 47 studies | — | — |
| Observational | 70 mo44–90 · 34 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 15, 2026.
Studies
Recruiting first, then most recently updated. Showing 50 of 343. Browse all 343 → or search them.
- A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-KitRecruitingNCT06805825Phase 11 country
- Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Phase 2/32 countries
- A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)RecruitingNCT06630234Phase 1/21 country
- Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic AnalysisRecruitingNCT045579691 country
- A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)RecruitingNCT06760819Phase 211 countries
- A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT06655246Phase 11 country
- A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)RecruitingNCT07585266Phase 320 countries
- ctDNA-Guided Sunitinib And Regorafenib Therapy for GISTRecruitingNCT05366816Phase 21 country
- Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal TumorsNot yet recruitingNCT07647068Phase 21 country
- A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib TherapyRecruitingNCT07218926Phase 319 countries
- A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and PimitespibRecruitingNCT07689201Phase 21 country
- A Legacy Study in Participants With Gastrointestinal Stromal Tumors (GIST)Not yet recruitingNCT07843641Phase 2
- DESTINY-PANTUMOUR04RecruitingNCT071240001 country
- Individual Patient Expanded Access for Velzatinib (GSK6042981) in Patients With Gastrointestinal Stromal Tumours With KIT MutationsAvailableNCT07825701
- Imatinib TDM in GISTRecruitingNCT05493215Phase 21 country
- KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)RecruitingNCT07406633Phase 21 country
- A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF AlterationsRecruitingNCT05503797Phase 212 countries
- Hyperpolarized MRI for GIST on ImatinibNot yet recruitingNCT077246261 country
- Study of DCC-2618 in Patients With GIST After at Least 3 Prior TreatmentsRecruitingNCT07618377Phase 11 country
- LRG GIST Patient RegistryRecruitingNCT076972481 country
- Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal TumorsAvailableNCT069489551 country
- Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer PatientsRecruitingNCT07673861Not applicable1 country
- Integrated Cancer Repository for Cancer ResearchRecruitingNCT020126991 country
- (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal TumorsRecruitingNCT05208047Phase 322 countries
- Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal TumorRecruitingNCT07171203Phase 11 country
- A Novel Two-Tooth Clip for ESD and EFTR of GISTRecruitingNCT07581977Not applicable1 country
- PH 2 Pemigatinib in SDH-deficient GISTRecruitingNCT07434843Phase 21 country
- Mesenteric Vascular Preconditioning Combined With Laparoscopic and Endoscopic Cooperative Surgery for Submucosal Tumor at the Gastroesophageal JunctionEnrolling by invitationNCT07550582Phase 21 country
- Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard TreatmentRecruitingNCT07559864Phase 21 country
- MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMTRecruitingNCT06748690Not applicable1 country
- Long-term Survivorship Challenges of Advanced/Metastatic GIST Patients Responding to Tyrosine Kinase Inhibitor Treatment: an Observational StudyRecruitingNCT075227621 country
- A Study of HQP1351 in Patients With GIST or Other Solid TumorsRecruitingNCT03594422Phase 11 country
- Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal TumorRecruitingNCT05905887Phase 21 country
- The Efficacy and Safety of Temozolomide in SDH-deficient GISTRecruitingNCT05661643Phase 21 country
- GIST Oral Paclitaxel(Liporaxel)RecruitingNCT06326346Phase 21 country
- Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote MonitoringRecruitingNCT05500391Phase 21 country
- RCT of EFTR Versus STER for GIST TreatmentRecruitingNCT07411118Not applicable4 countries
- Clinical & Pathological Studies of Upper Gastrointestinal CarcinomaRecruitingNCT010482811 country
- A Comprehensive, Multinational GIST RegistryNot yet recruitingNCT072730451 country
- Resistance Profiling Using Functional Imaging and Next Generation Sequencing in Refractory Gastrointestinal Stomal Tumors (GIST)Not yet recruitingNCT071090241 country
- 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High RiskRecruitingNCT05385549Phase 21 country
- CEH-EUS for Differentiating GISTs and Leiomyomas: A Multicenter Prospective Self-Controlled StudyNot yet recruitingNCT071064111 country
- Multicenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor DiagnosisRecruitingNCT070781361 country
- A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard TreatmentNot yet recruitingNCT06772233Phase 21 country
- An International Study on Pediatric Patients With Rare Tumors.RecruitingNCT070721431 country
- Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic SurgeryRecruitingNCT06926374Not applicable1 country
- Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORKRecruitingNCT041819708 countries
- The Correlation Between Ripretinib Exposure and the Efficacy and Safety in Patients with Advanced GISTsRecruitingNCT064314511 country
- Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRARecruitingNCT054616641 country
- A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal TumorsRecruitingNCT054648751 country